


|                         |   |   |
|-------------------------|---|---|
| <b>Name</b>             | <b>David Kendler</b>                        |  |
| <b>Current Position</b> | <b>Professor Medicine (Endocrinology)</b>   |   |
| <b>Country</b>          | <b>Canada</b>                               |   |
| <b>Major Field</b>      | <b>Osteoporosis, Metabolic bone disease</b> |   |

## Educational Background

Dr. Kendler graduated from the MD program at the University of Toronto in 1977. After completing a rotating internship in Toronto, he practiced for several years in Canada, Botswana, and New Zealand. He returned to Internal Medicine training in 1983 in Christchurch, New Zealand and in 1984 joined the Internal Medicine program in Halifax, Canada. In 1985 he moved to Vancouver to complete Internal Medicine and Endocrinology training at the University of British Columbia. After a 2-year thyroid immunology Fellowship in New York, he returned to the University of British Columbia Faculty of Medicine where he is now a Professor of Medicine in Endocrinology.

## Professional Experience

. He has led osteoporosis programs at Children and Women's Hospital and St. Paul's Hospital. He is the director of Prohealth Clinical Research, a major North American centre for clinical trials in the area of osteoporosis.

## Other Experience and Professional Memberships

He serves on the Scientific Advisory Council of Osteoporosis Canada and Chairs the Western Osteoporosis Alliance. He is a Past-President of the International Society for Clinical Densitometry. He is a member of the Committee of Scientific Advisors of the International Osteoporosis Foundation and is co-Chair of the Western Osteoporosis Alliance. He has been awarded the John Bilezikian ISCD Global Leadership Award and the IOF President's award. He has served on the Board of Directors of the Canadian Menopause Society.



## Main Scientific Publications

He has published over 140 peer-reviewed papers on osteoporosis therapies, osteoporosis risk assessment and autoimmune thyroid disease.

1. PMID: 34762286

[Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.](#)

Kendler DL, Cosman F, Stad RK, Ferrari S. *Adv Ther.* 2021 Nov 11. doi: 10.1007/s12325-021-01936-y. Online ahead of print. PMID: 34762286 Review.

□ 2. PMID: 33996429

[Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.](#)

Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Ebeling PR, Rizzoli R. *J Bone Oncol.* 2021 Apr 23;28:100361. doi: 10.1016/j.jbo.2021.100361. eCollection 2021 Jun. PMID: 33996429 **Free PMC article.** Review.

□ 3. PMID: 33211870

[Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.](#)

Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, Kendler D, Messina O, Miller PD. *J Clin Endocrinol Metab.* 2021 Jan 23;106(2):397-409. doi: 10.1210/clinem/dgaa851. PMID: 33211870 **Free PMC article.**

□ 4. PMID: 32820138

[Exploring Fear of Falling and Exercise Self-Efficacy in Older Women With Vertebral Fractures.](#)

Ponzano M, Gibbs JC, Adachi JD, Ashe MC, Cheung AM, Hill KD, Kendler D, Khan AA, McArthur C, Papaioannou A, Thabane L, Wark JD, Giangregorio LM. *J Aging Phys Act.* 2020 Aug 19;29(2):219-224. doi: 10.1123/japa.2019-0485. PMID: 32820138

□ 5. PMID: 32712739

[A scorecard for osteoporosis in Canada and seven Canadian provinces.](#)

Kendler DL, Adachi JD, Brown JP, Juby AG, Kovacs CS, Duperrouzel C, McTavish RK, Cameron C, Slatkowska L, Burke N. *Osteoporos Int.* 2021 Jan;32(1):123-132. doi: 10.1007/s00198-020-05554-2. Epub 2020 Jul 25. PMID: 32712739 **Free PMC article.** Review.

□ 6. PMID: 32613409

[Persistence and adherence to parenteral osteoporosis therapies: a systematic review.](#)

Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C. *Osteoporos Int.* 2020 Nov;31(11):2093-2102. doi: 10.1007/s00198-020-05507-9. Epub 2020 Jul 1. PMID: 32613409

□ 7. PMID: 32474650

[Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial.](#)

Body JJ, Marin F, Kendler DL, Zerbini CAF, López-Romero P, Mörnicke R, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Minisola S, Geusens P. *Osteoporos Int.* 2020 Oct;31(10):1935-1942. doi: 10.1007/s00198-020-05463-4. Epub 2020 May 30. PMID: 32474650 **Free PMC article.**

□ 8. PMID: 32219499

[Describing the resource utilisation and costs associated with vertebral fractures: the Build Better Bones with Exercise \(B3E\) Pilot Trial.](#)

Hassan S, Seung SJ, Clark RE, Gibbs JC, McArthur C, Mittmann N, Thabane L, Kendler D,

Papaioannou A, Wark JD, Ashe MC, Adachi JD, Templeton JA, Giangregorio LM. Osteoporos Int. 2020 Jun;31(6):1115-1123. doi: 10.1007/s00198-020-05387-z. Epub 2020 Mar 26. PMID: 32219499 Clinical Trial.

□ 9. PMID: 32157334

Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.

Geusens P, Kendler DL, Fahrleitner-Pammer A, López-Romero P, Marin F. Calcif Tissue Int. 2020 Jun;106(6):646-654. doi: 10.1007/s00223-020-00683-6. Epub 2020 Mar 10. PMID: 32157334 Clinical Trial.

□ 10. PMID: 32092479

Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed.

Ferrari S, Lewiecki EM, Butler PW, Kendler DL, Napoli N, Huang S, Crittenden DB, Pannacciulli N, Siris E, Binkley N. Bone. 2020 May;134:115287. doi: 10.1016/j.bone.2020.115287. Epub 2020 Feb 21. PMID: 32092479 Clinical Trial.

□ 11. PMID: 31899499

The Effects of Home Exercise in Older Women With Vertebral Fractures: A Pilot Randomized Controlled Trial.

Gibbs JC, McArthur C, Wark JD, Thabane L, Scherer SC, Prasad S, Papaioannou A, Mittmann N, Laprade J, Kim S, Khan A, Kendler DL, Hill KD, Cheung AM, Bleakney R, Ashe MC, Adachi JD, Giangregorio LM. Phys Ther. 2020 Apr 17;100(4):662-676. doi: 10.1093/ptj/pzz188. PMID: 31899499 **Free PMC article.** Clinical Trial.

□ 12. PMID: 31786954

The association between trunk muscle endurance, balance and falls self-efficacy in women with osteoporotic vertebral fractures: an exploratory analysis from a pilot randomized controlled trial.

McArthur C, Gibbs JC, Ashe MC, Cheung AM, Hill KD, Kendler DL, Khan A, Prasad S, Thabane L, Wark JD, Giangregorio LM. Disabil Rehabil. 2021 Aug;43(16):2268-2274. doi: 10.1080/09638288.2019.1696418. Epub 2019 Dec 1. PMID: 31786954 Clinical Trial.

□ 13. PMID: 31665314

Bone Mineral Density After Transitioning From Denosumab to Alendronate.

Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e255-64. doi: 10.1210/clinem/dgz095. PMID: 31665314 **Free PMC article.** Clinical Trial.

□ 14. PMID: 31654779

Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Kendler DL, Marin F, Geusens P, López-Romero P, Lespessailles E, Body JJ, Minisola S. Bone. 2020 Jan;130:115113. doi: 10.1016/j.bone.2019.115113. Epub 2019 Oct 22. PMID: 31654779 Clinical Trial.

□ 15. PMID: 31650166

Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".

Geusens P, Marín F, Kendler DL. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz122. doi: 10.1210/clinem/dgz122. PMID: 31650166 No abstract available.

□ 16. PMID: 31628490

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.

Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A. *Osteoporos Int*. 2019 Dec;30(12):2437-2448. doi: 10.1007/s00198-019-05146-9. Epub 2019 Oct 18. PMID: 31628490 **Free PMC article**. Clinical Trial.

□ 17. PMID: 31378452

Repeating Measurement of Bone Mineral Density when Monitoring with Dual-energy X-ray Absorptiometry: 2019 ISCD Official Position.

Kendler DL, Compston J, Carey JJ, Wu CH, Ibrahim A, Lewiecki EM. *J Clin Densitom*. 2019 Oct-Dec;22(4):489-500. doi: 10.1016/j.jocd.2019.07.010. Epub 2019 Jul 17. PMID: 31378452 Review.

□ 18. PMID: 31243557

Are osteoporotic vertebral fractures or forward head posture associated with performance-based measures of balance and mobility?

Ziebart C, Gibbs JC, McArthur C, Papaioannou A, Mittmann N, Laprade J, Kim S, Khan A, Kendler DL, Wark JD, Thabane L, Scherer SC, Prasad S, Hill KD, Cheung AM, Bleakney RR, Ashe MC, Adachi JD, Giangregorio LM. *Arch Osteoporos*. 2019 Jun 26;14(1):67. doi: 10.1007/s11657-019-0626-x. PMID: 31243557

□ 19. PMID: 31152714

Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis.

Lewiecki EM, Kendler DL, Davison KS, Hanley DA, Harris ST, McClung MR, Miller PD. *Am J Med*. 2019 Nov;132(11):e771-e777. doi: 10.1016/j.amjmed.2019.04.044. Epub 2019 May 29. PMID: 31152714 Review.

□ 20. PMID: 31125092

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.

Ferrari S, Butler PW, Kendler DL, Miller PD, Roux C, Wang AT, Huang S, Wagman RB, Lewiecki EM. *J Clin Endocrinol Metab*. 2019 Aug 1;104(8):3450-3461. doi: 10.1210/jc.2019-00271. PMID: 31125092 Clinical Trial.

□ 21. PMID: 31111878

Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors.

Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P, Holzer G, Kendler D, Napoli N, Pierroz DD, Rizzoli R, Brandi ML. *Ann Oncol*. 2019 Jun 1;30(6):908-920. doi: 10.1093/annonc/mdz120. PMID: 31111878 Review.

□ 22. PMID: 30820733

Exploring the association between number, severity, location of fracture, and occiput-to-wall distance.

Ziebart C, Adachi JD, Ashe MC, Bleakney RR, Cheung AM, Gibbs JC, Hill KD, Kendler DL, Khan AA, Kim S, McArthur C, Mittmann N, Papaioannou A, Prasad S, Scherer SC, Thabane L, Wark JD, Giangregorio LM. *Arch Osteoporos*. 2019 Feb 28;14(1):27. doi: 10.1007/s11657-019-0582-5. PMID: 30820733

□ 23. PMID: 30659410

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Minisola S, Marin F, Kendler DL, Geusens P, Zerbini CAF, Russo LA, Casado E, Fahrleitner-

Pammer A, Stepan JJ, Lespessailles E, Moericke R, Bagur A, Lakatos P, López-Romero P, Body JJ. Arch Osteoporos. 2019 Jan 18;14(1):10. doi: 10.1007/s11657-019-0561-x. PMID: 30659410 Clinical Trial.

□ 24. PMID: 30382319

[Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts' consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases \(ESCEO\) and the US branch of the International Osteoporosis Foundation.](#)

Hiligsmann M, Reginster JY, Tosteson ANA, Bukata SV, Saag KG, Gold DT, Halbout P, Jiwa F, Lewiecki EM, Pinto D, Adachi JD, Al-Daghri N, Bruyère O, Chandran M, Cooper C, Harvey NC, Einhorn TA, Kanis JA, Kendler DL, Messina OD, Rizzoli R, Si L, Silverman S. Osteoporos Int. 2019 Jan;30(1):45-57. doi: 10.1007/s00198-018-4744-x. Epub 2018 Oct 31. PMID: 30382319

□ 25. PMID: 30268814

[Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis.](#)

Díez-Pérez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M. Bone. 2019 Mar;120:1-8. doi: 10.1016/j.bone.2018.09.020. Epub 2018 Sep 27. PMID: 30268814

□ 26. PMID: 30244369

[The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies.](#)

Kendler DL, Chines A, Brandi ML, Papapoulos S, Lewiecki EM, Reginster JY, Muñoz Torres M, Wang A, Bone HG. Osteoporos Int. 2019 Jan;30(1):71-78. doi: 10.1007/s00198-018-4687-2. Epub 2018 Sep 22. PMID: 30244369 **Free PMC article.** Clinical Trial.

□ 27. PMID: 30178158

[Bone management in hematologic stem cell transplant recipients.](#)

Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Rizzoli R, Ebeling PR; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease. Osteoporos Int. 2018 Dec;29(12):2597-2610. doi: 10.1007/s00198-018-4669-4. Epub 2018 Sep 3. PMID: 30178158 Review.